Review of Toyoda K,
Antiplatelet agent
Cilostazol
Stroke
Journal
Surgical neurology international
ISSN: 2229-5097
Titre abrégé: Surg Neurol Int
Pays: United States
ID NLM: 101535836
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
03
2020
accepted:
04
03
2020
entrez:
5
5
2020
pubmed:
5
5
2020
medline:
5
5
2020
Statut:
epublish
Résumé
Prior meta-analyses showed that treatment with cilostazol, with or without aspirin, significantly reduced the incidence of recurrent ischemic stroke, occurrence of hemorrhagic stroke, and frequency of other serious vascular adverse events. This review highlights the value of the randomized controlled trial (RCT) by Toyoda Patients on dual therapy consisting of cilostazol/aspirin or cilostazol/clopidogrel had significantly lower frequencies of recurrent stroke. However, there were significant differences in the incidence of attendant hemorrhagic complications utilizing mono or dual therapy. This RCT demonstrated the safety of dual therapy, consisting of cilostazol/aspirin or cilostazol/ clopidogrel, in preventing secondary ischemic stroke in a high-risk Japanese population. Further studies are required to generalize these findings to other patient populations worldwide.
Sections du résumé
BACKGROUND
BACKGROUND
Prior meta-analyses showed that treatment with cilostazol, with or without aspirin, significantly reduced the incidence of recurrent ischemic stroke, occurrence of hemorrhagic stroke, and frequency of other serious vascular adverse events.
METHODS
METHODS
This review highlights the value of the randomized controlled trial (RCT) by Toyoda
RESULTS
RESULTS
Patients on dual therapy consisting of cilostazol/aspirin or cilostazol/clopidogrel had significantly lower frequencies of recurrent stroke. However, there were significant differences in the incidence of attendant hemorrhagic complications utilizing mono or dual therapy.
CONCLUSION
CONCLUSIONS
This RCT demonstrated the safety of dual therapy, consisting of cilostazol/aspirin or cilostazol/ clopidogrel, in preventing secondary ischemic stroke in a high-risk Japanese population. Further studies are required to generalize these findings to other patient populations worldwide.
Identifiants
pubmed: 32363048
doi: 10.25259/SNI_83_2020
pii: SNI-11-53
pmc: PMC7193192
doi:
Types de publication
Editorial
Langues
eng
Pagination
53Informations de copyright
Copyright: © 2020 Surgical Neurology International.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
BMJ Open. 2016 Mar 17;6(3):e009013
pubmed: 26988347
Expert Opin Pharmacother. 2018 Oct;19(15):1719-1726
pubmed: 30212227
Lancet Neurol. 2019 Jun;18(6):539-548
pubmed: 31122494